SRNE News and Press, Sorrento Therapeutics Inc. From 09/15/22

Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections achieved significant improvements in disease activity when switched to Sofusa lymphatic delivery. Re...

What Are The Best Penny Stocks To Buy This Week? This has been another wild week for penny stocks and higher-priced stocks. We started with an outlook on potential catalysts to watch for, which has remained a focus as market activity continues. Today, for example, market-moving events h...

SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D., Chairman, President and Chief Executive Officer, and members of Sorrento’s executive team will participate the 20 th Annual Mor...

During the first hour of trading Wednesday morning, shares of the commercial-stage biotech Sorrento Therapeutics (NASDAQ: SRNE) gapped up by as much as 8.3% on fairly heavy volume. Since this rocket-like start to today's trading session, the drugmaker's shares have cooled off to...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Toshio Chan / Shutterstock.com NewAge (NASDAQ: NBEV ) stock is in the spotlight Wednesday after the company filed for Chapter 11 bankruptcy protection . This saw the company filing for protection in t...

Sorrento Therapeutics, Inc. ( NASDAQ: SRNE ) has traded higher in early market trading after news broke that the FDA granted fast track designation to Scilex's drug/device product. Chico's FAS, Inc. ( NYSE: CHS ) also ticked upward as it beat on its latest earnings ...

The U.S. Food and Drug Administration (FDA) granted fast track designation to Scilex's drug/device product candidate SP-103 to treat acute low back pain (LBP). Scilex — which is over 99.9% owned by Sorrento Therapeutics ( NASDAQ: SRNE ) ...

SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure collection of appropriate data needed to support drug approval. ...

Shares of the commercial-stage biotech Sorrento Therapeutics (NASDAQ: SRNE) are having a strong trading session Tuesday. Specifically, the drugmaker's stock was up by a respectable 6.7%, on average volume, as of 2:34 p.m. ET Tuesday. What's powering Sorrento's stock higher t...

Sorrento Therapeutics ( NASDAQ: SRNE ) said that a pivotal study of its candidate abivertinib in non-small cell lung cancer demonstrated an overall response rate of 56.5% . In addition, results showed that 11 patients had complete responses ("CR") for a CR ra...